LC-MS/MS is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
Regulatory bodies treat GW501516 as a prohibited substance in competitive sport. The World Anti-Doping Agency added it to the prohibited list, and it falls under classes covering metabolic modulators and hormone-related agents. It is not approved by drug regulators for human use, and it is not a lawful dietary supplement. Products sold under the cardarine name may contain unlisted ingredients or different compounds. Because no approved product exists, quality and identity are not guaranteed by pharmaceutical manufacturing standards.
Cardarine is a common name for the investigational chemical GW501516, also written GW-1516. It was developed as a peroxisome proliferator-activated receptor delta agonist for metabolic conditions such as dyslipidemia. Early research focused on lipid handling and energy use in skeletal muscle and other tissues. The compound was never approved as a medicine. In public discussion, it is often grouped with performance-enhancing substances, although its receptor target differs from that of anabolic steroids or selective androgen receptor modulators. Regulatory and health authorities have issued warnings about its use.
GW501516 acts on PPARδ, a nuclear receptor that helps regulate fatty acid oxidation and energy homeostasis. In animal studies, activation of this receptor was associated with increased endurance and changes in lipid metabolism. Human trials examined effects on blood lipids and other metabolic markers, but the compound did not advance to approval. Rodent studies later reported tumors in multiple tissues at doses used in those experiments. Whether those findings translate to human risk remains uncertain, and the clinical relevance of the animal data is still debated.
In the fitness and bodybuilding literature, cardarine is frequently discussed as an endurance agent or fat-loss compound, although such claims are not supported by robust clinical evidence. Online descriptions often mix animal data, user anecdotes, and marketing language. Researchers who study PPARδ agonists distinguish between receptor activation in controlled experiments and unsupervised use of unverified products. The latter introduces unknown purity, dose, and interactions, making reported experiences difficult to interpret scientifically.
GW501516 acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in transcription of genes related to lipid handling and energy use. Activation of PPARδ can shift skeletal muscle toward greater fatty acid oxidation in animal models, which is one reason it drew interest for metabolic disease and exercise research. The exact downstream effects depend on tissue, species, dose, and duration. Human data are sparse, so many proposed benefits remain hypotheses rather than established clinical outcomes.
Laboratory studies have examined GW501516 in cell cultures and rodents for conditions such as dyslipidemia, insulin resistance, and obesity. Some trials in humans were initiated, but development was discontinued after preclinical findings raised concerns about cancer in certain models. Those findings do not prove that the compound causes cancer in people, but they contributed to regulatory caution. Later reviews often describe the evidence as preliminary and insufficient for assessing long-term safety.
| Property | Value | Notes |
|---|---|---|
| Common name | Cardarine | Common internet and media name. |
| Research code | GW501516 | Also written GW-1516. |
| Drug class | PPARδ agonist | Not a selective androgen receptor modulator. |
| Development status | Discontinued | Clinical development halted after rodent cancer findings. |
| Regulatory status | Prohibited in sport | Listed by WADA; not approved as medicine. |
PPARδ is a nuclear receptor that regulates gene expression related to fatty acid oxidation, glucose homeostasis, and mitochondrial function. GW501516 binds to this receptor with high affinity and activates downstream signaling in skeletal muscle and other tissues. Animal studies reported increased endurance and altered fuel preference, but human data remain limited and inconsistent. The precise relationship between receptor activation and observed physiological changes is still an area of active investigation. Researchers have also examined whether the compound affects inflammation or cell proliferation. No approved therapeutic indication exists for cardarine.
In laboratory settings, cardarine is studied as a tool compound for probing PPARδ biology. Published experiments often use cell cultures, rodent models, or isolated tissues. Some investigations focus on metabolic effects, while others assess potential risks such as carcinogenicity observed in long-term animal studies. Because human trials are sparse, most knowledge comes from preclinical work and adverse event reports. Scientific literature frequently notes the gap between animal findings and human outcomes. The compound is not a dietary supplement and is not intended for human consumption.
Cardarine is a common name for GW501516, a synthetic compound developed in the 1990s through research collaborations involving GlaxoSmithKline. It belongs to a class of molecules known as peroxisome proliferator-activated receptor delta agonists. Early studies explored its effects on lipid metabolism and energy expenditure in animal models. The compound was never approved as a human medicine, and clinical development was discontinued. In the years since, it has appeared in fitness and bodybuilding communities as a performance-enhancing substance. Regulatory agencies classify it as an unapproved drug.
Cardarine can be detected in biological samples and product materials using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). The method separates compounds by chromatography and identifies them by mass-to-charge transitions, allowing low-level detection in urine or blood. Sample preparation often involves enzymatic hydrolysis, solid-phase extraction, or protein precipitation. Certified reference materials and isotope-labeled internal standards improve quantification. Detection windows depend on metabolism, matrix, and assay sensitivity, so no single universal window applies.
Regulatory treatment of cardarine differs by context and jurisdiction. In competitive sport, the World Anti-Doping Agency lists PPARδ agonists, including GW501516, as prohibited at all times. Outside sport, it lacks approval as a prescription medicine in major drug markets, and products sold for human consumption may be treated as unapproved drugs. Some countries also restrict importation or sale through general consumer protection and medicines laws. These classifications affect availability, testing, and legal risk without establishing therapeutic value.
The pharmacological interest in cardarine centers on PPARδ activation and its downstream effects on lipid handling and mitochondrial function. In animal studies, PPARδ agonists have been associated with changes in exercise endurance and fatty acid utilization, though results vary by model and protocol. Human data remain sparse, and the absence of large controlled trials limits conclusions about efficacy. Researchers often describe the compound as a tool for probing PPARδ biology rather than a proven therapeutic agent.
Safety discussions about cardarine frequently cite rodent carcinogenicity findings reported in the 2000s. In those studies, treated animals developed tumors at multiple sites, leading sponsors to discontinue clinical development. The relevance of these findings to humans has not been resolved, but they are a major reason the compound is not approved. Current literature emphasizes uncertainty about long-term effects and the risks of unregulated use. Regulators and health agencies have not established a safe human exposure level.
Cardarine is a synthetic compound also known as GW501516, GW-501516, and sometimes endurobol. It was developed as a selective agonist of peroxisome proliferator-activated receptor delta, a nuclear receptor involved in fatty acid oxidation and energy metabolism. The compound was studied in preclinical models for metabolic and cardiovascular conditions, but it did not become a marketed human medicine. In regulatory and anti-doping contexts, it is treated as a prohibited substance rather than a licensed medicine.
Cardarine is a common name for GW501516, a synthetic compound studied for its effects on lipid and glucose metabolism. It functions as an agonist at peroxisome proliferator-activated receptor delta, or PPARδ, a nuclear receptor that influences gene expression. The molecule is not a steroid, nor is it a selective androgen receptor modulator. It is also known in research and sports literature as GW-501516 and endurobol. Early laboratory work examined its metabolic activity in cell cultures and animal models.
Activation of PPARδ changes transcription of genes involved in fatty acid transport, mitochondrial function, and skeletal muscle fuel preference. In rodent studies, pharmacological PPARδ activation was associated with increased endurance and altered body composition. These findings generated interest in performance enhancement, but species differences and study designs limit direct extrapolation to humans. Small human trials were conducted in the 2000s and later discontinued. The extent to which cardarine produces similar metabolic or performance effects in people remains an open question.
The compound is typically described as a laboratory compound rather than a therapeutic product. Published reports have explored its role in lipid disorders, insulin sensitivity, and exercise metabolism, yet no major drug regulator has approved it for medical use. Commercial samples sold under the cardarine name may vary in purity and identity. Analytical confirmation is therefore necessary when the material is discussed in scientific or regulatory contexts. Its classification as a prohibited substance in sport further shapes how it is studied and reported.
Where space is limited, such as on pressure gauges, name plates, graph labels, and table headings, the use of a modifier in parentheses, such as "kPa (gauge)" or "kPa (absolute)", is permitted. In non-SI technical work, a gauge pressure of 32 psi (220 kPa) is sometimes written as "32 psig", and an absolute pressure as "32 psia", though the other methods explained above that avoid attaching characters to the unit of pressure are preferred. Gauge pressure is the relevant measure of pressure wherever one is interested in the stress on storage vessels and the plumbing components of fluidics systems. However, whenever equation-of-state properties, such as densities or changes in densities, must be calculated, pressures must be expressed in terms of their absolute values. For instance, if the atmospheric pressure is 100 kPa (15 psi), a gas (such as helium) at 200 kPa (29 psi) (gauge) (300 kPa or 44 psi [absolute]) is 50% denser than the same gas at 100 kPa (15 psi) (gauge) (200 kPa or 29 psi [absolute]). Focusing on gauge values, one might erroneously conclude the first sample had twice the density of the second one.
On 7 April, Hikmat al-Hijri dissolved the Supreme Legal Committee in Suwayda, the judge Shadi Fayez Murshid was tasked with forming the Administrative Council of Jabal Bashan. On 11 April, people went to the streets at al-Karama Square to show their support for Hikmat al-Hijri. On 12 April 2026, clashes occurred between the Syrian Armed Forces and the National Guard along Maghdal–Mazraa. The next day, clashes took place between the Syrian Armed Forces and the National Guard along the Tel Hadid–industrial area. On 13 April, clashes between the Syrian Armed Forces and the National Guard took place along the Tel Hadid–industrial area. Also an assassination attempt was made against Anad Makarem, after he threatened the National Guard with a "popular uprising", Makarem was left in critical condition. On 15 April, the rival Druze leader Munir Najib al-Bahri was killed by unknown assailants. On 27 April, it was reported that the car of commander Basel al-Shaer was targeted. On 28 April, it was reported that the home of Rawad Abdul Khaleq, commander of the “Rapid Intervention” battalion in the National Guard, was attacked with gunfire and that the car of commander Farouk al-Naddaf was targeted with a Molotov cocktail.
== Career == Coon was a postdoctoral student in Donald Hunt's lab at the University of Virginia from 2002 to 2005. There Joshua Coon and John Syka developed electron-transfer dissociation (ETD). In 2005, Coon joined the University of Wisconsin-Madison. He became an associate professor in 2010, and a professor in 2012.
He then encounters Eddie at a computer in the company boardroom, who demands his release for making the reactor work. Paul agrees but Lyman refuses, so Eddie sets the reactor to explode while sending proof of his innocence to the FBI and blueprints of the reactor to "hopefully a couple thousand" international scientists. Lyman responds by shooting Chen dead, then locking in Eddie and Lily to die in the explosion as he, Paul, and their staff flee the site. Lyman is given a falsified copy of the fusion data before Paul kills him for overstepping the bounds of the program, leaving his body in an elevator. During his own escape, he deactivates the containment system, allowing Eddie and Lily to escape. They are attacked by Reed and Butler over an ascending construction lift but escape by climbing aboard it moments before a blast wave sweeps through the complex, incinerating the corpses of Reed, Butler, and Lyman. Having survived the shockwave, Eddie and Lily are met by FBI agents Ford and Doyle, now convinced of their innocence, who take them to safety. Paul is shown dictating a memo to Anita in a chauffeured limo, informing the Director of the CIA that "...C-System [is] no longer a viable entity." In a post-credits scene, the C-Systems facility is seen imploding into the landscape.
DiCaprio is agnostic. His personal life is the subject of widespread media attention, though he rarely grants interviews and is reluctant to discuss his private life. Since his 40s, DiCaprio has been the focus of various reports detailing his involvement with women aged 25 or younger, and has faced criticism for the age disparity of those relationships. In 1999, DiCaprio met Brazilian model Gisele Bündchen, whom he dated until 2005. He was romantically involved with Israeli model Bar Refaeli from 2005 to 2011. He later dated German fashion model Toni Garrn from 2013 to 2014 and later in 2017. DiCaprio was briefly romantically linked with Barbadian singer Rihanna, with the pair attending Coachella together in 2016. DiCaprio successfully sued French tabloid Oops after it made claims that DiCaprio had gotten Rihanna pregnant. DiCaprio was in a relationship with American model and actress Camila Morrone from 2017 until 2022. He has been dating Italian model Vittoria Ceretti since August 2023. DiCaprio owns houses in Los Angeles and apartments in New York City. In 2009, he bought an island, Blackadore Caye, off mainland Belize—on which he is set to open an environmentally friendly resort—and in 2014, he purchased the original Dinah Shore residence designed by architect Donald Wexler in Palm Springs, California. In 2005, DiCaprio's face was severely injured when model Aretha Wilson hit him over the head with a broken bottle at a Hollywood party. As a result, he required seventeen stitches to his face and neck.
Sources: en.wikipedia.org
Cross-matching or crossmatching is a test performed before a blood transfusion as part of blood compatibility testing. Normally, this involves adding the recipient's blood plasma to a sample of the donor's red blood cells. If the blood is incompatible, the antibodies in the recipient's plasma will bind to antigens on the donor red blood cells. This antibody-antigen reaction can be detected through visible clumping or destruction of the red blood cells, or by reaction with anti-human globulin. Along with blood typing of the donor and recipient and screening for unexpected blood group antibodies, cross-matching is one of a series of steps in pre-transfusion testing. In some circumstances, an electronic cross-match can be performed by comparing records of the recipient's ABO and Rh blood type against that of the donor sample. In emergencies, blood may be issued before cross-matching is complete. Cross-matching is also used to determine compatibility between a donor and recipient in solid organ transplantation including heart/lung transplation.
DMF penetrates most plastics and makes them swell. Because of this property DMF is suitable for solid phase peptide synthesis and as a component of paint strippers. DMF is used as a solvent to recover olefins such as 1,3-butadiene via extractive distillation. It is used in the manufacturing of solvent dyes as an important raw material. It is consumed during reaction. Pure acetylene gas cannot be compressed and stored without the danger of explosion. Industrial acetylene is safely compressed in the presence of dimethylformamide, which forms a safe, concentrated solution. The casing is also filled with agamassan, which renders it safe to transport and use. As a cheap and common reagent, DMF has many uses in a research laboratory.
light red or dark pink, being perfused with new capillary loops or "buds"; soft to the touch; moist; bumpy (granular) in appearance, due to punctate hemorrhages; pulsatile on palpation; painless when healthy;
Rapidly progressive glomerulonephritis, also known as crescentic GN, is characterised by a rapid, progressive deterioration in kidney function. People with rapidly progressive glomerulonephritis may present with a nephritic syndrome. In management, steroid therapy is sometimes used, although the prognosis remains poor. Three main subtypes are recognised:
Sources: en.wikipedia.org
No. Cardarine is a PPARδ agonist, while selective androgen receptor modulators act on androgen receptors. The two classes differ in receptor target and downstream effects.
Preclinical rodent studies reported cancers, including liver and bladder tumors, at tested doses. The human relevance of those findings is uncertain, but development was discontinued. No approved human product resulted.
No. It remains an investigational compound without approved therapeutic labeling. Sports regulators prohibit its use, and health agencies have warned against consuming it.
It binds and activates PPARδ, a nuclear receptor that influences gene expression related to fatty acid metabolism and energy balance. This mechanism has been studied mainly in animals and cell models, not established as a safe human therapy.